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Summary
Background Several small studies on patients with COVID-19 and haematological malignancies are available showing 
a high mortality in this population. The Italian Hematology Alliance on COVID-19 aimed to collect data from adult 
patients with haematological malignancies who required hospitalisation for COVID-19.
Methods This multicentre, retrospective, cohort study included adult patients (aged ≥18 years) with diagnosis of a 
WHO-defined haematological malignancy admitted to 66 Italian hospitals between Feb 25 and May 18, 2020, with 
laboratory-confirmed and symptomatic COVID-19. Data cutoff for this analysis was June 22, 2020. The primary 
outcome was mortality and evaluation of potential predictive parameters of mortality. We calculated standardised 
mortality ratios between observed death in the study cohort and expected death by applying stratum-specific mortality 
rates of the Italian population with COVID-19 and an Italian cohort of 31 993 patients with haematological 
malignancies without COVID-19 (data up to March 1, 2019). Multivariable Cox proportional hazards model was used 
to identify factors associated with overall survival. This study is registered with ClinicalTrials.gov, NCT04352556, and 
the prospective part of the study is ongoing.
Findings We enrolled 536 patients with a median follow-up of 20 days (IQR 10–34) at data cutoff, 85 (16%) of whom were 
managed as outpatients. 440 (98%) of 451 hospitalised patients completed their hospital course (were either discharged 
alive or died). 198 (37%) of 536 patients died. When compared with the general Italian population with COVID-19, the 
standardised mortality ratio was 2·04 (95% CI 1·77–2·34) in our whole study cohort and 3·72 (2·86–4·64) in individuals 
younger than 70 years. When compared with the non-COVID-19 cohort with haematological malignancies, the 
standardised mortality ratio was 41·3 (38·1–44·9). Older age (hazard ratio 1·03, 95% CI 1·01–1·05); progressive disease 
status (2·10, 1·41–3·12); diagnosis of acute myeloid leukaemia (3·49, 1·56–7·81), indolent non-Hodgin lymphoma 
(2·19, 1·07–4·48), aggressive non-Hodgkin lymphoma (2·56, 1·34–4·89), or plasma cell neoplasms (2·48, 1·31–4·69), 
and severe or critical COVID-19 (4·08, 2·73–6·09) were associated with worse overall survival.
Interpretation This study adds to the evidence that patients with haematological malignancies have worse outcomes 
than both the general population with COVID-19 and patients with haematological malignancies without COVID-19. 
The high mortality among patients with haematological malignancies hospitalised with COVID-19 highlights the need 
for aggressive infection prevention strategies, at least until effective vaccination or treatment strategies are available.
Funding Associazione italiana contro le leucemie, linfomi e mieloma–Varese Onlus.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Introduction
An outbreak of a previously unknown coronavirus, named 
severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2), was first detected in Wuhan, China, in 
December, 2019.1 In March, 2020, WHO declared 
COVID-19, the disease caused by SARS-CoV-2, a global 
pandemic. As of Aug 2, 2020, there have been more 
than 18·1 million cases of SARS-CoV-2 infection 
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worldwide, with comorbidities shown to affect disease 
severity and patient outcomes.2–6 Severe cases of COVID-19 
are characterised by an intense immune response with 
subsequent cytokines release syndrome and endothelial 
damage.7 Among patients with COVID-19, 3·7% have 
been found to have conditions characterised by 
immunodeficiency.8 The potential threat of COVID-19 to 
patients who are immu nocompromised because of cancer 
is thought to be substantial.9–13
Haematological malignancies such as leukaemias, 
myelodysplastic syndromes, myeloproliferative neo-
plasms, lymphomas, and multiple myeloma can be 
potentially cured or have an improved survival in a 
sizeable fraction of cases; therefore, infections can 
shorten life expectancy. Patients with haematological 
malignancies have usually long-lasting immuno defic-
iency because of the malignancy itself, anticancer 
treatments, or as a consequence of procedures such as 
haematopoietic stem-cell trans plantation. Several small 
studies including case reports14–17 and small retrospective 
cohort studies17–19 have been published on the outcome 
of patients with haematological malignancies and 
COVID-19. As of June 22, 2020 (data cutoff for our study), 
Italy had 239 627 cases of COVID-19 according to the 
Istituto Superiore di Sanità, of whom 33 498 (13·9%) died.
The aim of the Italian Hematology Alliance on 
COVID-19 (ITA-HEMA-COV) project was to collect and 
analyse data from adult patients with haematological 
malignancies who required hospitalisation for COVID-19. 
Here, we report results from a cohort study of 66 hospitals 
in Italy. This effort will assist haematologists worldwide 
and National Health Commissions in their decision 
making process regarding preventive measures and 
treatment in this patient population.
Methods
Study design and participants
This multicentre, retrospective, cohort study involved 
66 haematology units in Italy (appendix pp 11–12). The 
ITA-HEMA-COV group worked on behalf of all Italian 
societies dealing with haematology: Società Italiana di 
Ematologia, Società Italiana di Ematologia Sperimentale, 
Gruppo Italiano Trapianto Midollo Osseo, Sorveglianza 
Epidemiologica Infezioni nelle Emopatie, and Fondazione 
Italiana Linfomi. We included consecutive adult patients 
(aged ≥18 years) with any comorbidity who were admitted 
between Feb 25 and May 18, 2020, with data cutoff for the 
analyses on June 22, 2020. Inclusion criteria were the 
presence of a WHO-defined haematological malignancy 
and symp tomatic and laboratory-confirmed SARS-CoV-2 
infection, tested by RT-PCR on nasopharyngeal swabs. 
The trial was approved by the institutional review board of 
each haematology unit. Written informed consent was 
collected from all patients except for those patients who 
were unable to give it (according to Italian law 9/2016 
Autorizzazione Generale Garante della Privacy).
Research in context
Evidence before this study
Several small studies are available describing the natural history 
of patients with haematological malignancies and COVID-19, 
the disease caused by severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2). We searched PubMed for studies 
of any type on any haematological malignancy published in 
English up to July 1, 2020, using the terms “COVID-19” and 
“haematological malignancy”. The peer-reviewed literature 
dedicated to patients with SARS-CoV-2 infection and 
haematological malignancies was mostly limited to case 
reports or small series. Three small cohorts (the largest with 
34 cases), not encompassing the whole spectrum of disease 
subtypes and treatments, suggested poor outcomes for this 
patient group, with a case fatality of 32–61%. One paper on 
chronic lymphocytic leukaemia reported an overall case fatality 
rate of 33%, but with 25% of patients still in hospital. In this 
study, so-called watch-and-wait and treated cohorts had similar 
rates of mortality (37% vs 32%).  As a result of the few studies 
available, statistical analysis is not yet sufficiently robust to 
assess events and risk factors that can predict death in this new 
clinical setting.
Added value of this study
To our knowledge, we report the largest series of patients 
with haematological malignancies and COVID-19 to date. 
Our population consists of most haematological malignancies 
with varying disease status, including patients with a wide age 
distribution, some of whom were on active treatment. 
Our findings of high overall mortality (37%) and excess of 
mortality in patients with haematological malignancies and 
COVID-19 compared with patients with haematological 
malignancies without COVID-19, as well as with the Italian 
population with COVID-19, will assist haematologists and 
national health commissions in their decision making 
processes regarding preventive measures and treatment in this 
patient population.
Implications of all the available evidence
The high mortality in this population of patients, some with 
the potential to receive curative treatment, has important 
practical implications for health-care systems: priority must 
be given to regular swab testing, development of specific 
treatment trials, and allocation of dedicated health-care 
resources toward this patient population. Withholding 
specific effective treatments during the pandemic does not 
seem to be justified, particularly as the immunosuppressive 
effect of treatments can be long lasting. If a vaccine becomes 
available, plans should be established for vaccinations of 
patients with haematological malignancies, their caregivers, 
and health-care workers.
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Procedures
Data on laboratory parameters, possible complications, 
drug exposure, and patient outcomes (ie, intensive care 
unit [ICU] admission, death, or hospital dis charge) were 
collected for all patients during hospitalisation. Data on 
patient characteristics and outcomes were extracted by 
study investigators from electronic medical records or 
clinical charts, including age, sex, Charlson Comorbidity 
Index, type and status of haematological malignancy, time 
since diagnosis of haematological malignancy to COVID-19 
diagnosis, time from last haematological malignancy 
therapy to COVID-19 diagnosis, and COVID-19 severity.
Diagnosis of haematological malignancy was made on 
the basis of the most recent WHO classification of 
haematopoietic tumours.20,21 We defined a patient as 
having progressive disease when the malignancy was 
not responding to active therapy and remission as no 
evidence of disease. We defined active therapy as a 
therapy delivered during admission for COVID-19 or that 
had ended within the past 3 months. All nasopharyngeal 
swabs for COVID-19 diagnosis were managed according 
to national recommendations.22 Severity of COVID-19 at 
admission was graded according to the China Centers for 
Disease Control and Prevention definitions: mild (non-
pneumonia and mild pneumonia), severe (dyspnoea, 
respiratory frequency ≥30 breaths per min, SpO2 ≤93%, 
PaO2/FiO2 <300, or lung infiltrates >50%), and critical 
(respiratory failure, septic shock, or multiple organ 
disfunction or failure).2
Mortality estimates for COVID-19 in the general Italian 
population were obtained from the Bollettino Sorveglianza 
Integrato of the Isituto Superiore di Sanità, released on 
June 23, 2020.23 Mortality for patients with haema tological 
malignancies without COVID-19 was calculated using 
data from 31 993 patients resident in Lombardy, who were 
diagnosed with haematological malignancies from 
Jan 1, 2007, to Feb 29, 2019, and were still alive on 
March 1, 2019 (non-COVID-19 cohort).
Outcomes
The primary outcomes were mortality among patients 
with haematological malignancies and COVID-19 and 
evaluation of potential predictive parameters of mortality, 
including biochemical parameters (haemoglobin, haema-
tocrit, platelets, leucocytes, lymphocytes, clotting tests, 
serum lactate dehydrogenase, and C-reactive protein), 
haematological malignancy characteristics (disease type, 
disease status, and therapy status), and COVID-19 severity. 
Secondary outcomes were epidemio logy of patients with 
haematological malignancies infected by SARS-CoV-2 
(ie, type of haematological malignancy, ICU admission 
rate, laboratory abnormalities, and haematological 
malignancy-specific treatments), evolution of haema to-
logical malignancies, and dynamics of viral load; results 
for the latter two are not presented in this Article. 
Although the prespecified plan was to report on the 
epidemiological outcomes at 6 months of follow-up, we 
report these outcomes early because the majority of 
patients had completed their hospital stay.
Statistical analysis
Continuous variables are expressed as mean (SD) or 
median (IQR). We used the independent group t test to 
analyse normally distributed continuous variables and 
the Mann-Whitney U test for non-normally distributed 
continuous variables. Normality was verified using the 
Shapiro-Wilks test and graphically using Q–Q plot. 
Categorical variables are presented as frequencies and 
percentages, and were analysed using the χ² test. 
Characteristics of the study population were described 
for survivors and non-survivors and overall incidence of 
ICU admission was calculated. Among patients with 
severe or critical COVID-19, the Fine and Gray model 
was applied to study patient characteristics (age, Charlson 
Comorbidity Index, type and status of haematological 
malignancy) associated with ICU admission, treating 
death as a competing event in the univariate model. The 
features of our cohort study were finally compared 
according to COVID-19 severity (severe or critical vs mild) 
using the t test, Mann-Whitney U test, or χ² test, as 
appropriate.
The mortality rate for COVID-19 was calculated as the 
ratio between the number of deaths in patients with 
COVID-19 and the person-time at risk. Person-time was 
calculated as the time between date of COVID-19 diag-
nosis and date of death by any cause, hospital discharge, 
or last follow-up, whichever occurred first. In a post-hoc 
analysis, Poisson regression models were used to 
compare mortality of patients enrolled in the first period 
of the study (Feb 25–March 31) versus those enrolled in 
the second period (April 1–May 18) and between 
individuals treated in northern versus southern Italy 
(including Sardinia and Sicily). We compared overall 
survival in patients with different COVID-19 severity by 
Kaplan-Meier with the log rank test. We provide two 
standardised mortality ratios: one comparing mortality of 
the study cohort with that of the general Italian 
population with COVID-19 and the second comparing 
mortality of the study cohort with the Lombardy 
population with haematological malignancies without 
COVID-19 (non-COVID-19 cohort). Standardised mor-
tality ratios are calculated as the ratio between observed 
deaths in the study cohort and expected deaths, calculated 
as stratum-specific mortality rates of the comparison 
cohorts (indirect standardisation). When comparing with 
the general Italian population with COVID-19, mortality 
rates were stratified according to sex and age. When 
comparing with the non-COVID-19 cohort, mortality 
rates in the comparison cohort were calculated in the 
period March 1–June 22, 2019 (ie, the equivalent time 
period of the study cohort, but in 2019) and were stratified 
according to sex, age, type of haematological malignancy, 
and disease duration. Wald 95% CIs were calculated by 
assuming observed deaths followed a Poisson 
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distribution. Using a multivariable Cox propor tional 
hazards model, we evaluated association with overall 
survival of the following variables: age, sex, Charlson 
Comorbidity Index, type and status of haematological 
malignancy, time from haema tological malignancy to 
COVID-19 diagnosis, time from last haematological 
malignancy therapy to COVID-19 diag nosis, and 
COVID-19 severity. The proportional hazard assumption 
was tested with incorporation of time-dependent 
covariates. Multi collin earity was investigated with the 
variance inflation factor and tolerance. We did an 
exploratory analysis on the association of biochemical 
variables with overall survival. For baseline laboratory 
values, median and 95% CIs were obtained with 
1000 bootstrap simulations for survivors and non-
survivors separately; the 95% CI for difference of 
medians between the two groups was also calculated 
with the same method. Finally, we did a descriptive 
exploratory analysis on special clinical situations 
(eg, haematopoietics stem-cell trans plan tation) and 
treatments received for haemato logical malignancies. All 
statistical analysis was done with SAS version 9.4. This 
study is registered with ClinicalTrials.gov, NCT04352556, 
and the prospective part of the study is ongoing.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. All authors had full access to the data and had 
final responsibility for the decision to submit for 
publication.
Results
536 patients with haematological malignancies who were 
admitted for inpatient (n=451) or outpatient (n=85) care 
to manage symptomatic COVID-19 were enrolled 
(figure 1). Median follow-up was 20 days (IQR 10–34; 
range 1–98), with last contact on June 22. Among 
451 hospitalised patients, 440 (98%) completed their 
hospital course (were either discharged or died) with a 
median length of hospital stay of 16 days (9–29; range 
1–98); median length of hospital stay was 20 days (12–36; 
range 2–98) for survivors and 11 days (6–21; range 1–78) 
for non-survivors. 82 (18%) of 451 hospitalised patients 
required ICU admission: 50 (11%) patients required 
immediate admission to the ICU whereas 32 (8%) of 
401 patients who were initially not admitted to the ICU 
were later transferred there. Within patients with severe 
or critical COVID-19—ie, potential candidates for ICU 
admission—the Fine and Gray model showed that those 
admitted to the ICU were younger (hazard ratio 
[HR] 0·97, 95% CI 0·96–0·98) and had a lower Charlson 
Comorbidity Index (HR 0·80, 0·71–0·91).
Patients’ baseline characteristics are shown in table 1 
by survival status, with haematological malignancies 
subtypes detailed in the appendix (pp 2–3). The most 
common symptoms at time of hospital admission for 
COVID-19 were fever (337 [75%] of 451 patients), 
dyspnoea (231 [51%] patients), cough (204 [45%] patients), 
and malaise (175 [39%] patients; appendix p 4). Vascular 
events were evident in 33 (5%) patients (appendix p 4). 
Headaches occurred in 28 (6%) patients and diarrhoea in 
42 (9%) patients.
268 (50%) of 536 patients had mild COVID-19 (84 of 
whom were managed as outpatients), 194 (36%) patients 
had severe COVID-19 (one of whom was managed as an 
outpatient), and 74 (14%) patients had critical COVID-19 
(figure 1). Clinical characteristics by COVID-19 severity 
are reported in the appendix (p 5). In univariate analysis, 
patients with severe or critical disease were older (mean 
age 68·0 years [SD 12·8] vs 65·5 years [13·7]; p=0·032), 
had a higher Charlson Comorbidity Index (mean 5·0 [2·3] 
vs 4·4 [2·4]; p=0·011), and a more recent diagnosis of 
haematological malignancy (median time from diagnosis 
0 years [IQR 2–6] vs 1 year [0–5]; p=0·0032) than patients 
with mild COVID-19 (appendix p 5).
At data cutoff, 198 (37%) of 536 patients had died, with 
a mortality rate of 153·2 deaths (95% CI 129·7–172·1) per 
10 000 person-days. During the first study period 
(Feb 25–March 31), the mortality rate was 169·2 deaths 
(143·9–198·9) per 10 000 person-days, whereas during 
the second study period (April 1–May 18) it was 
significantly lower, at 111·1 deaths (84·4–146·2) per 
10 000 person-days (Wald χ² test; p=0·014). No significant 
difference in mortality rate was detected between 
northern (150·8 deaths [129·4–175·9] per 10 000 person-
days) and southern (141·6 deaths [101·7–197·2] per 
10 000 person days) Italy (Wald χ² test; p=0·73). 52 (63%) 
of 82 patients admitted to the ICU and 146 (32%) of 
Figure 1: Study profile
All patients were included in mortality analyses. SARS-CoV-2=severe acute respiratory syndrome coronavirus 2. 
ICU=intensive care unit. *Analysed for complications.
85 admitted for outpatient care
 84 with mild disease
1 with severe disease
536 enrolled
582 patients with haematological malignancies 
diagnosed with COVID-19 assessed for 
eligibility
46 excluded
10 with non-haematological malignancies
36 without confirmed SARS-CoV-2 positivity
451 admitted for inpatient care 
(11 still hospitalised)*
184 with mild disease
193 with severe disease
74 with critical disease
50 admitted to the ICU 401 not admitted to the ICU
369 never admitted
32 later admitted to the ICU
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454 patients not admitted to the ICU died. Patients with 
severe or critical COVID-19 had worse overall survival 
than patients with mild COVID-19 (appendix p 10).
When comparing mortality in the study cohort with the 
Italian population with COVID-19, the standardised 
mortality ratio was 2·04 (95% CI 1·77–2·34) in the whole 
study population, 3·72 (2·86–4·64) in people younger 
than 70 years, and 1·71 (1·44–2·04) in people aged 70 years 
or older (figure 2). When comparing mortality in the study 
cohort with the non-COVID-19 cohort with haematological 
malignancies, 853 (2·7%) of 31 993 patients in the 
non-COVID-19 cohort died, with a mortality rate of 
2·42 deaths (2·26–2·58) per 10 000 person-days and a 
resulting standardised mortality ratio of 41·3 (38·1–44·9).
In the multivariable Cox regression model, older age; 
progressive disease status; diagnosis of acute myeloid 
leukaemia, indolent non-Hodgkin lymphoma, aggressive 
non-Hodgkin lymphoma, or plasma cell neoplasms; and 
severe or critical COVID-19 at admission were associated 
with worse survival (table 2).
In an exploratory analysis in 308 patients with data on 
laboratory findings at admission (176 survivors, 132 non-
survivors), non-survivors had lower haemoglobin values 
(median difference −1·5 g/dL, 95% CI −2·0 to −0·2) and 
platelet count (−65 000 platelets per μL, −95 250 to −17 000) 
and higher serum lactate dehydrogenase (125 U/L, 
56 to 215) than did survivors (appendix p 6).
251 (56%) of 451 patients had at least one complication 
during hospitalisation. Additional infec tions occurred in 
187 (41%) of 451 patients, alteration of organ damage 
biomarkers in 124 (27%) patients, and vascular events in 
50 (11%) patients. The proportion of non-survivors 
experiencing complications was numeri cally higher 
than the proportion of survivors (figure 3). After 
admission, treatments for COVID-19 were administered 
according to institutional guidelines (appendix p 7). In 
the 451 hospitalised patients, 295 (65%) patients were 
treated with hydroxychloroquine (of whom 99 [34%] 
died), 188 (42%) with antiviral agents (of whom 71 [38%] 
died), 135 (30%) with heparins (of whom 46 [34%] died), 
and 40 (9%) with tocilizumab (of whom 16 [40%] died).
82 patients underwent haema topoietic stem-cell 
transplantation before SARS-CoV-2 infection, 31 (38%) of 
which were allogeneic (appendix p 8). Death occurred in 
11 (35%) of 31 patients who received allogeneic haemato-
poietic stem-cell transplan tation and in 17 (33%) of 
51 who received autologous transplantation. 16 allogeneic 
transplantations and three autologous transplantations 
had been done in the previous 6 months; four of these 
patients died, all of whom had received allogeneic 
transplantation.
233 patients were on active therapy when diagnosed 
with COVID-19, 90 (39%) of whom died (appendix p 9). 
Of patients with acute myeloid leukaemia, 11 (33%) of 
33 patients receiving chemotherapy and one (12%) of 
eight patients on azacytidine–decitabine died. Among 
patients with myeloproliferative neo plasms, all 11 patients 
with chronic myeloid leukaemia receiving tyrosine 
kinase inhibitors (TKIs) were alive at data cutoff, whereas 
four (44%) of nine patients with polycythaemia vera or 
All patients (n=536) Survivors (n=338) Non-survivors (n=198)
Age, years
Mean 66·8 (13·3) 64·0 (13·6) 71·5 (11·5)
Median 68 (58–77) 64 (55–73) 73 (66–80)
Age group, years
<50 62 (12%) 51 (15%) 11 (6%)
50–59 86 (16%) 68 (20%) 18 (9%)
60–69 137 (26%) 100 (30%) 37 (19%)
70–79 158 (29%) 79 (23%) 79 (40%)
≥80 93 (17%) 40 (12%) 53 (27%)
Sex
Female 196 (37%) 133 (39%) 63 (32%)
Male 340 (63%) 205 (61%) 135 (68%)
Charlson Comorbidity Index
Mean 4·7 (2·4) 4·2 (2·3) 5·5 (2·3)
Median 4 (3–6) 4 (3–6) 5 (4–7)
Coexisting conditions
Heart disease 82 (15%) 43 (13%) 39 (20%)
Pulmonary disease 43 (8%) 24 (7%) 19 (10%)
Vascular disease 91 (17%) 51 (15%) 40 (20%)
Connective tissue diseases 13 (2%) 9 (3%) 4 (2%)
Liver disease 34 (6%) 16 (5%) 18 (9%)
Kidney disease 42 (8%) 18 (5%) 24 (12%)
Diabetes 72 (13%) 42 (12%) 30 (15%)
Non-haematological cancer 51 (10%) 25 (7%) 26 (13%)
Type of haematological malignancy
Myeloid neoplasms 175 (33%) 106 (31%) 69 (35%)
Myeloproliferative neoplasms 83 (15%) 56 (17%) 27 (14%)
Myelodysplastic syndromes 41 (8%) 21 (6%) 20 (10%)
Acute myeloid leukaemias 51 (10%) 29 (9%) 22 (11%)
Acute lymphoblastic leukaemias 16 (3%) 13 (4%) 3 (2%)
Hodgkin lymphoma 17 (3%) 14 (4%) 3 (2%)
Non-Hodgkin lymphomas 222 (41%) 138 (41%) 84 (42%)
Chronic lymphoproliferative 
neoplasms
69 (13%) 47 (14%) 22 (11%)
Indolent lymphomas 54 (10%) 33 (10%) 21 (11%)
Aggressive lymphomas 99 (18%) 58 (17%) 41 (21%)
Plasma cell neoplasms 106 (20%) 67 (20%) 39 (20%)
Time since haematological 
malignancy diagnosis, years
2 (0–6) 2 (0–6) 2 (0–5)
Time since last therapy for 
haematological malignancy, 
months
1 (0–12) 1 (0–12) 1 (0–13)
Haematological malignancy status: 
progressive disease
81 (15%) 33 (10%) 48 (24%)
COVID-19 disease severity
Mild 268 (50%) 220 (65%) 48 (24%)
Severe 194 (36%) 106 (31%) 88 (44%)
Critical 74 (14%) 12 (4%) 62 (31%)
Data are n (%), median (IQR), or mean (SD).
Table 1: Baseline characteristics and coexisting conditions by survival status
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myelofibrosis receiving ruxolitinib died. Among patients 
with non-Hodgkin lymphomas, four (31%) of 13 patients 
on rituximab alone as maintenance, 27 (47%) of 57 on 
rituximab–chemotherapy, and eight (44%) of 18 on 
chemotherapy alone died. Nine patients with chronic 
lymphocytic leukaemia were receiving ibrutinib at the 
time of COVID-19 diagnosis, of whom five (56%) died. 
Immunomodulatory drugs were given to 19 patients with 
multiple myeloma, of whom eight (42%) died.
Discussion
In the COVID-19 pandemic, patients with haematological 
malignancies are potentially a high-risk population 
because of intrinsic frailty, immunosuppressive thera pies, 
and frequent hospital visits for treatment delivery. In our 
study, 198 (37%) of 536 patients with haema tological 
malignancies had died by data cutoff. Some smaller 
cohorts have found similarly poor outcomes for this 
patient group, with mortality ranging from 32% to 61% of 
patients.17,18
Clinical features of COVID-19 reported from the 
Chinese population were mainly fever (44% on admis-
sion) and cough (68%), with 5% of patients admitted to 
the ICU.6 Mortality was 1·4% in a Chinese study 
including 926 patients with non-severe COVID-19,6 
rising when patients with severe disease were included: 
mortality was 10% in 393 cases from two centres in the 
New York City area (with 33% of patients receiving 
invasive mechanical ventilation)4 and 21% in 5700 cases 
from the Northwell COVID-19 Research Consortium 
(14% of whom were admitted to the ICU).3 In patients 
who received a solid organ transplantation, the mortality 
rate has been found to be around 20–30%.24,25
Our study population developed COVID-19-related 
symptoms similarly to those reported in healthy 
individuals, which suggests a common host response to 
the virus. However, severe forms of disease were more 
frequent in patients with haematological malignacies: 
dyspnoea occurred in 51% of patients (vs 17·3% in New 
York City3 and 19% in China6) and fever in 75% of patients 
(vs 31% in New York City3). Mild symptoms such as 
headache and diarrhoea occurred in less than 10% of our 
hospitalised patients, similarly to the general popu-
lation.3,6 Overall, 50% of our patients had severe or critical 
COVID-19. This finding clearly indicates that patients 
with haematological malignancies represent a high-risk 
population with poor COVID-19 outcomes, even when 
compared with patients with solid tumours (17% rate of 
case fatality13). This is also evident by the high proportion 
(18%) of patients admitted to the ICU, which is similar to 
that reported in patients with solid tumours (7–15%).11,13 
Insufficient ICU capacity is one of the known problems 
of the COVID-19 pandemic, since those with severe 
disease who are excluded have reduced chance of 
survival. Within patients with severe or critical disease, 
we found that those admitted to the ICU were younger 
and had a lower Charlson Comorbidity Index than those 
who were not admitted. Measures to reduce outbreak 
magnitude in this pandemic, such as preventive 

























Deaths/patients Hazard ratio 
(95% CI)
Age (per year increase) ·· 1·03 (1·01–1·05)
Sex
Female 63/196 0·86 (0·60–1·24)
Male 135/340 1 (ref)






Type of haematological malignancy
Myeloproliferative neoplasms 27/83 1 (ref)
Myelodysplastic syndromes 20/41 1·58 (0·69–3·62)
Acute myeloid leukaemias 22/51 3·49 (1·56–7·81)
Acute lymphoblastic leukaemias 3/16 1·65 (0·46–5·94)




Indolent lymphomas 21/54 2·19 (1·07–4·48)
Aggressive lymphomas 41/99 2·56 (1·34–4·89)
Plasma cell neoplasms 39/106 2·48 (1·31–4·69)
Time since haematological 
malignancy diagnosis (per year 
increase)
·· 1·01 (0·97–1·04)





Mild 48/268 1 (ref)
Severe or critical 150/268 4·08 (2·73–6·09)
Table 2: Independent predictors of mortality from multivariable Cox 
regression model
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lockdowns and physical distancing measures, are 
imperative to ensure less pressure on ICUs.
When comparing mortality in our cohort with the 
general population with COVID-19, the standardised 
mortality ratio in patients younger than 70 years was 3·72, 
meaning that mortality of patients with haematological 
malignancies and COVID-19 was nearly four times higher 
than that of the general population with COVID-19. In the 
haematology setting, patients younger than 70 years are 
often candidates for treatments such as haematopoietic 
stem-cell transplantation and they have a high chance of 
achieving potential cure or long-term survival. When 
comparing our cohort with a non-COVID-19 cohort with 
haematological malignancies, we found a stan dardised 
mortality ratio of 41·3, meaning that mortality of patients 
with haematological malignancies and COVID-19 was 
41 times higher than that of such patients without 
SARS-CoV-2 infection. We found a mortality rate of 
2·42 deaths per 10 000 person-days in patients with 
haematological malignancies in 2019, which increased to 
153·2 deaths per 10 000 person-days in patients with 
COVID-19 who were managed in 2020. This information 
has important practical implications for health-care 
systems: priority should be given to regular swab testing, 
development of specific treatment trials, and allocation of 
dedicated health-care resources towards this category of 
patients.
Overall survival was independently predicted by age, 
type of malignancy, disease status, and the severity of 
COVID-19. We found that older age was significantly 
associated with worse overall survival, as expected from 
data in the general population, whereas comorbidities 
were not. In addition, progressive disease status and 
diagnosis of acute myeloid leukaemia, non-Hodgkin 
lymphomas, and plasma cell neoplasms were predictive 
for a poor outcome. Progressive disease status is also 
associated with COVID-19 survival in solid cancer 
cohorts.10 We found no association between overall 
survival and time since haematological malignancy 
diagnosis or last treatment for haematological malig-
nancies. Thus, it seems that patients with haematological 
malignancies are at high risk of mortality regardless of 
whether they have recent disease or are on specific 
therapy, or both. Finally, our data showed that COVID-19 
severity was independently associated with worse overall 
survival.
A study on solid cancers has shown that cytotoxic 
chemotherapy delivered within 4 weeks before COVID-19 
diagnosis had no effect on overall survival.11 We therefore 
investigated COVID-19 mortality according to treatment 
in the 233 patients who were receiving therapy at the time 
of COVID-19 diagnosis or who had received therapy 
within the previous 3 months (immunosuppressive effect 
of treatments is mostly long lasting). Of note, all patients 
with chronic myeloid leukaemia who received TKIs were 
still alive at data cutoff, suggesting these patients, when 
receiving optimal care, have a well controlled disease and 
are thus at low risk of mortality according to the predictors 
we identified. We also found lower mortality in patients 
with follicular lymphoma receiving rituximab as main-
tenance therapy after remission (31%) than when 
combined with chemo therapy (47%), which was similar 
to mortality in patients treated with chemotherapy 
alone (44%).
When taken together, our findings suggest that 
withholding specific effective treatments from patients 
with haematological malignancies during the COVID-19 
pandemic is not justified, especially as the immunosup-
pressive effect of treatments is long lasting. In the case of 
SARS-CoV-2 infection, disease type and status are the 
major drivers of outcome.
The data we present on mortality might facilitate 
patient–doctor communication on COVID-19-related 
risks for patients with haematological malignancies. We 
conclude that meticulous preventive measures are crucial 
in this setting and future trials on specific antiviral 
treatments are urgently required. If a COVID-19 vaccine 
is successfully developed, plans must be established for 
future priority vaccination of patients, caregivers, and 
health-care workers.
Data from randomised controlled trials on COVID-19 
treatments have not shown any benefit for remdesivir,26 
lopinavir–ritonavir,27 or hydroxychloroquine.28 Preliminary 
data have shown that tocilizumab, a monoclonal antibody 
targeting interleukin-6 receptor, can improve the clinical 
outcome in patients with severe or critical disease.29 Our 
study adds some preliminary information on drugs that 
are currently under investigation for treatment of 
COVID-19, such as ruxolitinib, a Janus kinase inhibitor,30 
and ibrutinib, a Bruton TKI. We found that 44% of 
patients receiving ruxolitinib and 55% of patients 
receiving ibrutinib died. Our data did not indicate a clear 
protective or adverse effect of Bruton TKI therapy, as 
reported by Mato and colleagues.31
Limitations of our study include the retrospective nature 
of the study, the lack of power to support firm conclu sions, 
the heterogeneity of haematological malignancies 
Figure 3: Complications during hospitalisation among survivors and non-survivors
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included, and potential issues with generalisability to non-
haematological malignancies, benign haematological dis-
orders, or cancer. We did not include  patients who were 
asymptomatic or were not tested for SARS-CoV-2 infection 
(during February and March, routine swab testing of 
asymptomatic people was not allowed by the Italian 
Government), which is likely to have resulted in a higher 
mortality rate in our cohort.
In conclusion, the high mortality among patients with 
haematological malignancies who were hospitalised 
with COVID-19 highlights the need for aggressive 
infection prevention, at least until effective vaccination 
or treatment strategies are available. Delivering efficient 
therapies for haematological malignancies despite the 
pandemic continues to be a challenge needing further 
research.
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